The city of Boston, Massachusetts, currently has 31 active clinical trials seeking participants for Pancreatic Cancer research studies.
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949
Recruiting
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Dana Farber Cancer Center, Boston, Massachusetts
Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Register for Updates
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Register for Updates
ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT06015659
Recruiting
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) Gemcitabine (a nucleoside metabolic inhibitor)
Gender:
All
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Video Education With Result Dependent dIsclosure
NCT05225428
Recruiting
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Register for Updates
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
Register for Updates
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT03104439
Recruiting
This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. The interventions involved in this study are: Nivolumab Ipilimumab Radiation Therapy
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts general Hospital, Boston, Massachusetts
Conditions: Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer
Register for Updates
FOLFIRINOX + NIS793 in Pancreatic Cancer
NCT05417386
Recruiting
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas adenocarcinoma. The drugs involved in this study are: NIS793 FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin) Other interventions include chemorad... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/19/2022
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Register for Updates